Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 5, 2010, Pages 1783-1786

  Coughlin, John E ^a   Padmanabhan, Seetharamaiyer ^a   Zhang, Guangrong ^a   Kirk, Cassandra J ^a   Govardhan, Chandrika P ^a   Korba, Brent E ^b   O'Loughlin, Kathleen ^c   Green, Carol E ^c   Mirsalis, Jon ^c   Morrey, John D ^d   Iyer, Radhakrishnan P ^a  

^a Spring Bank Pharmaceuticals Inc   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c SRI INTERNATIONAL   (United States)

^d UTAH STATE UNIVERSITY   (United States)

Author keywords

ADME studies; Anti HBV activity; Antiviral activity; Dinucleotide; Oral bioavailability; Prodrugs; Transgenic mouse model

Indexed keywords

ANTIVIRUS AGENT; DINUCLEOTIDE; PRODRUG; TRINUCLEOTIDE;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG IDENTIFICATION; HEPATITIS B VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; THIN LAYER CHROMATOGRAPHY; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTATION; NUCLEOTIDES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

HEPATITIS B VIRUS; MUS MUSCULUS;

EID: 76649142036     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.010     Document Type: Article

References (26)

1. Hepatitis B. Fact sheet WHO/204. Geneva: World Health Organization, October 2000. http://www.who.int/inf-fs/en/fact204.htm.
2. For reviews see:. Perrillo R.P. Semin. Liver Dis. 24 (2004) 23
3. Lavanchy D. J. Viral Hepat. 11 (2004) 97
4. Reviewed in:. Iyer R.P., Padmanabhan S., Zhang G., Morrey J.D., and Korba B.E. Curr. Opin. Pharmacol. 5 (2005) 520
5. Iyer R.P., Jin Y., Roland A., Morrey J.D., Mounir S., and Korba B. Antimicrob. Agents Chemother. 48 (2004) 2199
6. Iyer R.P., Roland A., Jin Y., Mounir S., Korba B., Julander J.G., and Morrey J.D. Antimicrob. Agents Chemother. 48 (2004) 2318
7. Padmanabhan S., Coughlin J.E., Zhang G., Kirk C.J., and Iyer R.P. Bioorg. Med. Chem. Lett. 16 (2006) 1491
8. Srivastva D.N., and Farquhar D. Bioorg. Chem. 12 (1984) 118
9. Iyer R.P., Phillips L.R., Biddle J.A., Thakker D.R., Egan W., Aoki S., and Mitsuya H. Tetrahedron Lett. 30 (1989) 7141
10. 6, δ ppm: 2, 28.1, 28.9; 3, 27.7, 28.6 ppm.
11. Halogen exchange reactions of chloromethyl esters were carried out with excess of sodium iodide (2 equiv) in anhydrous acetonitrile at rt overnight in the dark. After removal of the solvent, the reaction mixture was extracted between water and DCM, the DCM layer was washed with sodium bisulfite solution (5%), followed by brine, and dried over anhydrous sodium sulfate. The organic layer was concentrated to give the iodomethyl esters; also see:. Iyer R.P., Yu D., Ho N.-H., and Agrawal S. Synth. Commun. 25 (1995) 2739
12. For a review, see:. Beaucage S.L., and Iyer R.P. Tetrahedron 49 (1993) 1925
13. Padmanabhan S., Coughlin J.E., and Iyer R.P. Tetrahedron Lett. 46 (2005) 343
14. The LOTUS Reactor® is a new chemical reaction chamber designed and built by us for solid-phase synthesis; see:. Iyer R.P., Coughlin J.E., and Padmanabhan S. Org. Prep. Proc. Intl. 37 (2005) 205
15. Iyer R.P., Regan J.B., Egan W., and Beaucage S.L. J. Am. Chem. Soc. 112 (1990) 1253
16. Recently, we have also developed efficient solution-phase synthesis, which provides access to larger quantities of 1 in each batch run (unpublished results).
17. *Complete hydrolysis occured at both isomers.
18. For excellent reviews on the concept of pseudorotation in the hydrolysis of cyclic phosphates, see:. Westheimer F.H. Acc. Chem. Res. 1 (1968) 70
19. Singleton Jr. R.J. J. Chem. Educ. 50 (1973) 538
20. The United States Phamacopeia, 23rd ed. The National Formulary 18: p 2053, 1994 Rockville, MD.
21. p 3, 18.4 min, respectively.
22. 2O (δ 58.6, 58.8 ppm) was recorded and spectra obtained at different time points following the sequential addition of pepsin and DCl as per the SGF composition in Ref. 15 A significant decrease in the peak intensities at δ 58.6, 58.8 ppm was noted after 1 h thereby suggesting decomposition of 1 in SGF.
23. Shafiee M., Deferme S., Villard A.-L., Egron D., Gosselin G., Imbach J.-L., Lioux T., Pompon A., Varray S., Aubertin A.-M., Van Den Mooter G., Kinget R., Périgaud C., and Augustijns P. J. Pharm. Sci. 90 (2001) 448
24. 5
25. de Vrueh R.L.A., Smith P.L., and Lee C.-P. J. Pharmacol. Exp. Ther. 286 (1998) 1166
26. 4, 0.21 mg/ml salmon sperm DNA, and 7% SDS. The radioactive signals were measured using the phosphorimaging method (Optiquant). An image of the radioactive filter was exposed to a Cyclone™ Storage Phosphor Screen (Perkin Elmer Multisensitive Medium, Type MS PPN 7001723). The exposed screen was transferred to the Cyclone™ drum and read using the 600 dpi setting. The data was stored on a computer, and the density of the bands was measured. The ratio of the viral DNA bands to the transgene band was used to determine the concentration of viral DNA per host DNA. This calculation was based upon the knowledge that there were 1.3 copies of the transgene present per host cell with this line of transgenic mice (personal communication to JDM from F. Chisari). The transgene was used as an internal indicator to calculate the pg of HBV DNA per μg of cellular host DNA. The pg HBV DNA/μg host DNA was calculated.